- Ritter Pharmaceuticals - http://www.ritterpharmaceuticals.com -

Press Releases / News

Press Releases / News

2018

November – Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress [1]

November – Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants [2]

October – Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants [3]

October – Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting [4]

August – Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018 [5]

August – Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress [6]

June – Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance [7]

June – Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer [8]

June – Ritter Pharmaceuticals Highlights Key Phase 2b Clinical Trial Data of RP-G28 for Lactose Intolerance at Digestive Disease Week 2018 [9]

May – Ritter Pharmaceuticals Announces Appointment of John W. Beck as Chief Financial Officer [10]

May – Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance [11]

May – Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates [12]

May – Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance [13]

March – Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split [14]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update [15]

March – Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome [16]

March – Ritter Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13 [17]

March – Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split [18]

February – Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board [19]

January – Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial [20]

2017

November – Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017 [21]

November – Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress [22]

October – Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update [23]

October – Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance [24]

September – Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering [25]

August – Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance [26]

August – Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update [27]

August – Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms [28]

May – Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates [29]

May – Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3 [30]

April – Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities [31]

March – Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial [32]

February – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update [33]

February – Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy [34]

January – Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month [35]

January – Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome [36]

January – Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors [37]

January – Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences [38]

2016

November – CNBC Article by Andrew Ritter: A Race to Turn Trillions of Our Own Bacteria into Medical Breakthroughs [39]

November – Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016 [40]

November – Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update [41]

October – Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock [42]

October – Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock [43]

October – Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance [44]

October – Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum [45]

August – Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in  Lactose Intolerance [46]

August – Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update [47]

June – Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28 [48]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update [49]

March – Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance [50]

March – Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance [51]

March – Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference [52]

March – Ritter Pharmaceuticals, Inc. Featured in PharmaVOICE [53]

February – Ritter Pharmaceuticals Issued Two New Patents [54]

 

2015

December – Ritter Pharmaceuticals Enters Into a $10 Million Common
Stock Purchase Agreement with Aspire Capital Fund

November – Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update [55]

October – Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board [56]

October – Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer [57]

October – Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference [58]

September – Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum [59]

August – Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor [60]

June – Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering [61]

April – Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors [62]

April – Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors [63]

February – Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors [64]

 

2014

September – Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer [65]

May – Andrew Ritter Named Finalist for 2nd Consecutive Year in LA Business Journal’s Annual Healthcare Leadership Awards [66]

January – Ritter Pharmaceuticals Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal [67]

 

2013

October – Using Galacto-Oligosaccharides to Improve Lactose Tolerance: Food Technology [68]

June – Ritter Pharmaceuticals’ Study Shows That Altering the Intestinal Microbiome May Offer an Effective Treatment for Lactose Intolerance [69]

April – Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards [70]

April – Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance [71]

March – Ritter Pharmaceuticals Encouraged by Meeting with FDA [72]

February – Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer [73]

January – Survey: 75% of People with Lactose Intolerance Avoid Dairy Food [74]

January – Lactose Intolerance: Major Unmet Medical Need [75]

 

2012

July – Ritter Pharmaceuticals Appoints Michael Step to the Board of Directors [76]

May – Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012 [77]

February – Ritter Pharmaceuticals’ Abstract on RP-G28’s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012 [78]

January – Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial [79]

 

2011

December – Ritter Pharmaceuticals Appoints Robert H. Tidwell as Chief Business Officer [80]

November – Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance [81]

June – Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance [82]

 

2010

November – Ritter Pharmaceuticals, Inc. Awarded a Grant under the U.S. Qualified Therapeutic Discovery Project Program [83]

October – Ritter Pharmaceuticals, Inc. Wins Top Awards at Venture Capital Investment Competition [84]

October – Ritter Pharmaceuticals Wins 2010 San Diego Quick Pitch Competition [85]

June – Ritter Pharmaceuticals, Inc. Receives FDA IND Approval For Lactose Intolerance Treatment [86]

February – Ritter Pharmaceuticals, Inc. to Discuss Lactose Intolerance and Associated Health Risks at NIH Conference [87]

 

2009

September – Ritter Pharmaceuticals’ CEO, Andrew Ritter to Present at the 11th Annual SoCalBio Investor Conference [88]

September – Ritter Pharmaceuticals, Inc. Hires Dr. Howard Foyt as Exec VP, Development & Chief Medical Officer [89]